

Singular Health Group Ltd: SHG

ASX Announcement

15th May 2024

Significant Follow On Investment from Marin & Sons

HIGHLIGHTS

- Marin and Sons LLC, currently Singular Health's largest shareholder, to invest AUD\$773,000 at AUD\$0.16 per share as a follow-on investment to November 2023 Placement.
- Marin and Sons to waive monthly retainer for US Corporate Advisory and Public Relations services in favour of a purely success based remuneration structure.

15 May 2024 – Singular Health Group Limited (ASX: SHG, "Singular Health", or the "Company") is pleased to announce that it has further strengthened its balance sheet through a significant follow-on investment of AUD\$773,000 in a AUD\$0.16 per share premium placement to Marin and Sons LLC.

This investment comes on the back of Marin & Sons' substantial participation in the \$850,000 placement by CG1 Ventures in November 2023 at AUD\$0.055 and is being made at a 39% premium to Singular Health's last closing price of AUD\$0.115. This capital raising will be completed via a placement of 4,831,250 new fully paid ordinary shares at AUD\$0.16 per share and is subject to shareholder approval, which will be sought immediately at a general meeting.

In an additional show of confidence, Marin & Sons have agreed to a variation of their services agreement as the Company's US Public Affairs and Corporate Advisor waiving their monthly retainer in lieu of receiving 1 million performance rights that are to vest upon Singular Health receiving a binding, unconditional contract of a minimum total contract value of \$USD1,000,000 over 18 months, from a managed service organisation (MSO) in the United States. The issue of the performance rights is also subject to shareholder approval, and the performance rights and the capital raising shares will be subject to a 12-month escrow period.

Singular Health's Managing Director, Denning Chong, welcomed the follow on investment, saying:

"The introductions and in-country expertise provided by Steve Marin and his team has been instrumental in progressing Singular Health's commercialisation in the United States.

This large financial investment, in addition to their already substantial financial investment recently, demonstrates significant confidence by Marin and Sons in the commercial prospects of Singular Health's software and we look forward to advancing discussions with large healthcare groups in Florida and South-East USA."

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary support@singular.health

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, visit: www.singular.health and investors.singular.health